<?xml version='1.0' encoding='utf-8'?>
<document id="19752211"><sentence text="Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam."><entity charOffset="119-128" id="DDI-PubMed.19752211.s1.e0" text="triazolam" /></sentence><sentence text="CYP3A4 is an important determinant of drug-drug interactions" /><sentence text=" In this study, we evaluated whether cytochrome P450 3A knockout mice [Cyp3a(-/-)] and CYP3A4 transgenic (CYP3A4-Tg) mice can be used to study drug-drug interactions in the liver and intestine" /><sentence text=" Triazolam was used as a probe drug because it is a highly specific CYP3A substrate and not a P-glycoprotein substrate"><entity charOffset="1-10" id="DDI-PubMed.19752211.s4.e0" text="Triazolam" /></sentence><sentence text=" Triazolam metabolism was profoundly reduced in Cyp3a(-/-) mice both in vitro and in vivo"><entity charOffset="1-10" id="DDI-PubMed.19752211.s5.e0" text="Triazolam" /></sentence><sentence text=" In vitro studies revealed clear species differences in humans and mice, but triazolam metabolism in microsomes derived from CYP3A4-Tg &quot;humanized&quot; mice closely resembled that in human microsomes" /><sentence text=" It is interesting to note that studies with tissue-specific CYP3A4-Tg mice revealed that intestinal CYP3A4 has a major impact on oral triazolam exposure, whereas the effect of hepatic CYP3A4 was limited"><entity charOffset="135-144" id="DDI-PubMed.19752211.s7.e0" text="triazolam" /></sentence><sentence text=" To mimic a drug-drug interaction, we coadministered triazolam with the prototypical CYP3A inhibitor ketoconazole, which increased triazolam exposure in all the CYP3A-proficient mouse strains but not in Cyp3a(-/-) mice"><entity charOffset="53-62" id="DDI-PubMed.19752211.s8.e0" text="triazolam" /><entity charOffset="101-113" id="DDI-PubMed.19752211.s8.e1" text="ketoconazole" /><entity charOffset="131-140" id="DDI-PubMed.19752211.s8.e2" text="triazolam" /><pair ddi="false" e1="DDI-PubMed.19752211.s8.e0" e2="DDI-PubMed.19752211.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19752211.s8.e0" e2="DDI-PubMed.19752211.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19752211.s8.e0" e2="DDI-PubMed.19752211.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19752211.s8.e1" e2="DDI-PubMed.19752211.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19752211.s8.e1" e2="DDI-PubMed.19752211.s8.e2" /></sentence><sentence text=" We further found that the anticancer drug gefitinib is a potent stimulator of 1'-OH triazolam formation in vitro"><entity charOffset="43-52" id="DDI-PubMed.19752211.s9.e0" text="gefitinib" /><entity charOffset="79-94" id="DDI-PubMed.19752211.s9.e1" text="1'-OH triazolam" /><pair ddi="false" e1="DDI-PubMed.19752211.s9.e0" e2="DDI-PubMed.19752211.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19752211.s9.e0" e2="DDI-PubMed.19752211.s9.e1" /></sentence><sentence text=" It is noteworthy that we could also show in vivo stimulation of triazolam metabolism by gefitinib, resulting in a lower oral triazolam exposure"><entity charOffset="65-74" id="DDI-PubMed.19752211.s10.e0" text="triazolam" /><entity charOffset="89-98" id="DDI-PubMed.19752211.s10.e1" text="gefitinib" /><entity charOffset="126-135" id="DDI-PubMed.19752211.s10.e2" text="triazolam" /><pair ddi="false" e1="DDI-PubMed.19752211.s10.e0" e2="DDI-PubMed.19752211.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19752211.s10.e0" e2="DDI-PubMed.19752211.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19752211.s10.e0" e2="DDI-PubMed.19752211.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19752211.s10.e1" e2="DDI-PubMed.19752211.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19752211.s10.e1" e2="DDI-PubMed.19752211.s10.e2" /></sentence><sentence text=" To our knowledge, this is the first in vivo example of direct stimulation of CYP3A4 activity after oral drug administration" /><sentence text=" Overall, this study illustrates how Cyp3a(-/-) and CYP3A4-Tg mice can be used to study drug-drug interactions" /><sentence text=" The data clarify that for drugs that are not P-glycoprotein substrates, intestinal metabolism also can be more important than hepatic metabolism after oral administration" /><sentence text="" /></document>